Lower Drug Costs in the Doughnut Hole

The coverage gap in the Part D prescription-drug plan has started closing through a combination of government subsidies and drug-company discounts.

EDITOR'S NOTE: This article, which was originally published in the February 2011 issue of Kiplinger's Retirement Report, has been updated as of October 2011. To subscribe, click here.

Medicare beneficiaries have had much to celebrate this year. The dreaded "doughnut hole" in the Part D prescription-drug plan has started closing through a combination of government subsidies and drug-company discounts. By 2020, beneficiaries will pay just 25% of the costs of their generic and brand-name drugs while in the coverage gap.

Subscribe to Kiplinger’s Personal Finance

Be a smarter, better informed investor.

Save up to 74%
https://cdn.mos.cms.futurecdn.net/hwgJ7osrMtUWhk5koeVme7-200-80.png

Sign up for Kiplinger’s Free E-Newsletters

Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.

Profit and prosper with the best of expert advice - straight to your e-mail.

Sign up

To continue reading this article
please register for free

This is different from signing in to your print subscription


Why am I seeing this? Find out more here

Susan B. Garland
Contributing Editor, Kiplinger's Retirement Report
Susan Garland is the former editor of Kiplinger's Retirement Report, a personal finance publication whose subscribers are retirees and those approaching retirement. Before joining Kiplinger in 2006, Garland was a freelance writer whose work appeared in the New York Times, the Washington Post, BusinessWeek, Modern Maturity (now AARP The Magazine), Fortune Small Business and other publications. For 12 years, Garland was a Washington-based correspondent for BusinessWeek, covering the White House, national politics, social policy and legal affairs. Garland is a graduate of Colgate University.